Qiagen’s stock jumped as much as 20% after Bloomberg reported the company is exploring a potential sale and is in talks with advisers and suitors. Market commentary named Danaher and Agilent among strategic acquirers that could fit Qiagen’s molecular‑testing and life‑science tools profile, and noted board activity following CEO Thierry Bernard’s announced departure. Qiagen’s portfolio includes diagnostics, sample prep and recently announced deals such as the acquisition of Parse Biosciences. Analysts flagged consolidation in the life‑science tools and diagnostics sector as a driver of strategic interest in Qiagen, given fewer independent scale players remain after recent dealmaking. A sale process or formal auction would reshape the nucleic acid testing and molecular diagnostics landscape and could prompt competitive responses from major tools and diagnostics firms. Qiagen did not immediately comment on the report.